+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Kidney Cancer or Renal Cancer Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Stage (Localized, Locally Advanced, Metastatic), Treatment Line, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Kidney Cancer or Renal Cancer Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Stage (Localized, Locally Advanced, Metastatic), Treatment Line, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
New

Kidney Cancer or Renal Cancer Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Stage (Localized, Locally Advanced, Metastatic), Treatment Line, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6142006
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Setting the Stage for Kidney Cancer Therapeutics: Understanding Disease Burden, Clinical Challenges, and Emerging Solutions

Introduction

Kidney cancer, also known as renal carcinoma, represents a critical area of clinical focus due to its rising incidence and complex pathophysiology. Initially recognized primarily through imaging techniques, the disease often presents with nonspecific symptoms that challenge early detection efforts. Over the past decade, the diagnostic landscape has shifted toward advanced modalities, revealing a deeper understanding of tumor biology and heterogeneity.

Furthermore, therapeutic approaches have diversified beyond traditional surgery and radiation, spotlighting the need for an integrated framework that addresses both localized and systemic disease. Patient outcomes vary significantly based on disease stage and individual response, underscoring the importance of personalized treatment plans. As the scientific community uncovers novel biomarkers and resistance mechanisms, stakeholders across clinical, research, and commercial domains must adapt to a rapidly evolving environment.

Moreover, cross-disciplinary collaborations are becoming the cornerstone of innovation, with oncology specialists, molecular biologists, and digital health experts working in tandem. By viewing kidney cancer through a holistic lens, this report aims to synthesize key developments, outline shared challenges, and highlight emerging solutions poised to transform patient care and therapeutic accessibility.

Unraveling the Paradigm Shifts in Renal Cancer Care: Breakthrough Therapies, Precision Medicine, and Patient-Centric Models

Renal cancer care has undergone remarkable transformation driven by scientific breakthroughs and patient-centric initiatives. Initially, targeted therapies disrupted the status quo, offering more precise inhibition of molecular drivers such as VEGF and mTOR pathways. Following this shift, immunotherapy regimens, including CTLA-4 and PD-1 inhibitors, have redefined long-term disease management and survival prospects.

As the therapeutic toolbox expanded, precision medicine emerged as a key enabler, harnessing genomic profiling to guide treatment selection and combination strategies. Concurrently, digital health platforms integrated real-time patient monitoring and telemedicine, enhancing clinical trial enrollment and adherence. These shifts have been reinforced by an increased emphasis on multi-disciplinary tumor boards, which facilitate dynamic care pathways and iterative treatment adjustments based on evolving patient data.

Looking ahead, the convergence of molecular diagnostics, artificial intelligence, and adaptive trial designs promises further advancement. Yet, this momentum hinges on addressing regulatory complexity, ensuring equitable access, and fostering interoperability among data systems. By examining how these components coalesce, stakeholders can anticipate and shape the next wave of innovation in renal cancer management.

Evaluating the Cascading Effects of Upcoming US Tariff Changes in 2025 on Renal Cancer Treatment Accessibility and Supply Chain Dynamics

Evaluating proposed tariff adjustments set to take effect in 2025 reveals a multifaceted impact on the renal cancer treatment ecosystem. On one hand, increased import duties on specialized pharmaceuticals could elevate production costs, leading to tighter profit margins for multinational manufacturers. In parallel, domestic suppliers may face raw material price fluctuations that ripple through formulation and distribution networks.

Consequently, clinical research sponsors must recalibrate trial budgets to account for potential supply chain disruptions, while healthcare providers might confront higher procurement expenses. Reimbursement frameworks will need to adapt, balancing patient access with fiscal sustainability. Meanwhile, logistics partners may reexamine sourcing strategies, favoring local or regional suppliers to mitigate tariff exposure and maintain inventory resilience.

Ultimately, this environment underscores the importance of collaborative risk-sharing models among payers, providers, and industry. It also highlights the strategic value of diversifying manufacturing footprints and leveraging free trade agreements where possible. By understanding these dynamics in advance, decision-makers can devise proactive measures to safeguard treatment availability and preserve continuity of care.

Deriving Strategic Insights from Therapy Type, Disease Stage, Treatment Line, End User, and Distribution Channel Segmentation Dynamics

A nuanced examination of therapeutic segmentation reveals distinct drivers influencing clinical adoption and commercial traction. Treatments span chemotherapy, immunotherapy, radiation therapy, surgery, and targeted therapy, each addressing unique aspects of tumor biology and patient tolerability. Within the immuno-oncology space, agents such as CTLA-4 inhibitors, cytokine therapies, PD-1 inhibitors, and PD-L1 inhibitors demonstrate differentiated efficacy and safety profiles, prompting tailored regimen design.

Similarly, targeted therapies harness mTOR inhibitors, multikinase inhibitors, and VEGF inhibitors to disrupt critical signaling cascades. When evaluating disease stages, localized conditions often benefit from surgical interventions and adjuvant approaches, whereas locally advanced and metastatic stages demand systemic regimens and combination strategies. Treatment line considerations further refine decision-making: first-line therapies set the stage for long-term outcomes, second-line protocols manage resistance, and third-line or higher options address refractory cases.

The end-user landscape spans ambulatory surgical centers, specialized cancer institutes, hospital systems, and growing home care services, each with distinct operational imperatives and reimbursement pathways. Distribution channels vary across hospital pharmacies, online platforms, and retail pharmacies, influencing patient experience and adherence. By integrating these segmentation insights, stakeholders can align research priorities, resource allocation, and go-to-market strategies with evolving clinical needs and patient expectations.

Analyzing Regional Trends in Americas, Europe Middle East & Africa, and Asia-Pacific Markets for Tailored Renal Cancer Healthcare Strategies

Regional differences shape the trajectory of renal cancer management by reflecting variations in healthcare infrastructure, regulatory environments, and patient demographics. In the Americas, robust clinical trial networks and reimbursement frameworks have accelerated the adoption of advanced immunotherapies and targeted agents. This region also exhibits a strong shift toward value-based care models and patient support programs aimed at reducing out-of-pocket burdens.

In Europe, Middle East & Africa, heterogeneous regulatory standards and economic landscapes influence market entry timings and pricing strategies. Leading markets in Western Europe prioritize early access schemes and real-world evidence generation, while emerging markets focus on capacity building and diagnostic expansion. In Africa and parts of the Middle East, efforts center on bolstering local manufacturing and cold-chain logistics to ensure treatment continuity.

Across Asia-Pacific, a blend of advanced and emerging economies presents unique opportunities for digital health integration and decentralized clinical trials. Patient advocacy and screening initiatives are gaining traction, supported by government-led cancer control programs and public-private partnerships. These varied regional dynamics reinforce the necessity for tailored market approaches that optimize clinical outcomes, regulatory alignment, and patient engagement.

Profiling Leading Innovators and Industry Veterans Driving Advancements in Renal Cancer Therapeutics and Diagnostic Solutions

Industry participants range from established pharmaceutical giants to nimble biotechnology firms and specialized diagnostics providers. Global companies have driven innovation through large-scale clinical programs, strategic alliances, and extensive R&D budgets, focusing on both monotherapy and combination regimens. Their portfolios often include well-characterized immuno-oncology compounds alongside emerging small molecules targeting key oncogenic pathways.

Conversely, emerging biotechs bring agility to the landscape by advancing novel modalities such as antibody-drug conjugates and bispecific antibodies. They frequently engage in collaborative development agreements with academic research centers, accelerating the translation of early-stage discoveries into clinical candidates. Diagnostic innovators contribute companion assays and liquid biopsy platforms that refine patient selection and monitor therapeutic response over time.

Service providers, including contract development and manufacturing organizations, enable scalable production and formulation optimization. By forging integrated value chains, these stakeholders collectively reduce time-to-clinic and enhance regulatory readiness. Understanding the interplay among these players-each with distinct strengths, pipelines, and strategic priorities-illuminates the competitive contours and partnership opportunities within the renal cancer ecosystem.

Strategic Roadmap for Stakeholders to Enhance Clinical Outcomes, Foster Collaboration, and Accelerate Innovation in Kidney Cancer Care

To capitalize on emerging opportunities and mitigate evolving risks, industry leaders should prioritize a multifaceted approach. First, forging strategic collaborations across academic, clinical, and commercial entities will streamline the translation of scientific breakthroughs into practice. Sharing real-world data and harmonizing trial protocols can accelerate evidence generation and regulatory approvals.

Simultaneously, investing in biomarker-driven research platforms will enable more precise patient stratification and reduce the likelihood of trial failures. By integrating advanced analytics and artificial intelligence, organizations can predict resistance mechanisms and tailor combination strategies proactively. Enhancing supply chain resilience through diversified manufacturing sites and alternative sourcing reduces exposure to tariff fluctuations and geopolitical disruptions.

Lastly, engaging with payers, policymakers, and patient advocacy groups to design value-based reimbursement frameworks will ensure broader access and alignment on evidence thresholds. Clear communication of clinical benefits and health economic outcomes can foster trust and facilitate adoption. Through these concerted efforts, stakeholders can drive sustainable progress, optimize patient outcomes, and maintain a competitive edge.

Comprehensive Methodological Framework Combining Quantitative Analysis, Qualitative Insights, and Robust Data Validation for Market Research Excellence

The research underpinning this analysis employs a rigorous, multi-pronged methodology designed to ensure validity and relevance. Primary data collection included in-depth interviews with oncology clinicians, R&D executives, and health economics experts, yielding qualitative insights into treatment barriers and unmet needs. Secondary research encompassed peer-reviewed publications, regulatory filings, and conference proceedings to capture the latest therapeutic advances and clinical trial outcomes.

Quantitative modeling techniques were applied to evaluate treatment adoption patterns, distribution dynamics, and cost drivers, leveraging anonymized patient registries and healthcare utilization databases. Data triangulation across diverse sources minimized bias and enhanced the robustness of findings. In addition, a comprehensive regulatory landscape review assessed approval timelines, pricing frameworks, and policy shifts across key regions.

Throughout the process, a stringent validation protocol engaged a panel of independent subject matter experts for cross-verification. Feedback loops and iterative refinements ensured that conclusions reflect real-world clinical practice and emerging market forces. This systematic approach provides stakeholders with confidence in the insights and recommendations derived from the study.

Synthesizing Key Findings to Illuminate Future Pathways for Innovation, Access, and Patient-Centered Care in Renal Cancer Management

Bringing together the critical findings, the landscape of renal cancer care is defined by rapid innovation, shifting regulatory environments, and evolving patient expectations. Breakthroughs in immuno-oncology and targeted therapies have altered long-standing treatment paradigms, yet challenges remain in optimizing sequencing, managing resistance, and ensuring equitable access. Meanwhile, external factors such as tariff adjustments and supply chain resilience continue to shape operational strategies.

Regional nuances underscore the need for customized approaches, whether that involves leveraging real-world evidence in developed markets or investing in infrastructure and capacity in emerging territories. Segmentation insights highlight diverse clinical pathways from first-line protocols to later-line interventions, while distribution channel dynamics influence patient adherence and therapy continuity.

Ultimately, the synthesis of these insights points to a convergent future where collaboration, personalization, and value-based frameworks guide decision-making. By acting on the recommendations outlined-strengthening partnerships, embracing data-driven research, and advocating for supportive policies-stakeholders can navigate complexities and foster sustainable advancements in renal cancer management.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Type
    • Chemotherapy
    • Immunotherapy
      • CTLA-4 Inhibitor
      • Cytokine Therapy
      • PD-1 Inhibitor
      • PD-L1 Inhibitor
    • Radiation Therapy
    • Surgery
    • Targeted Therapy
      • MtOr Inhibitor
      • Multikinase Inhibitor
      • VegaF Inhibitor
  • Stage
    • Localized
    • Locally Advanced
    • Metastatic
  • Treatment Line
    • First Line
    • Second Line
    • Third Line Or Higher
  • End User
    • Ambulatory Surgical Center
    • Cancer Institute
    • Home Care
    • Hospital
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • AstraZeneca plc
  • Exelixis, Inc.
  • Novartis AG
  • Ipsen S.A.
  • Eisai Co., Ltd.
  • Merck KGaA

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging role of combination immunotherapy and tyrosine kinase inhibitors in treatment regimens for advanced renal cell carcinoma
5.2. Adoption of novel biomarker-driven precision therapy strategies to improve patient outcomes and reduce adverse effects
5.3. Increasing investments in next generation sequencing platforms for early detection and molecular profiling of renal tumors
5.4. Growth of patient-centric telemedicine services and digital monitoring platforms for post nephrectomy follow up care
5.5. Advancements in minimally invasive robotic-assisted surgical techniques for complex kidney cancer resections
5.6. Rising prevalence of combination checkpoint inhibitor regimens in first line metastatic renal cell carcinoma management
5.7. Rapid expansion of real-world evidence studies to evaluate long term safety and efficacy of targeted therapies in renal cancer
5.8. Surge in public private partnerships to accelerate clinical trial development for rare renal cell carcinoma subtypes
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Kidney Cancer or Renal Cancer Market, by Therapy Type
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.3.1. CTLA-4 Inhibitor
8.3.2. Cytokine Therapy
8.3.3. PD-1 Inhibitor
8.3.4. PD-L1 Inhibitor
8.4. Radiation Therapy
8.5. Surgery
8.6. Targeted Therapy
8.6.1. MtOr Inhibitor
8.6.2. Multikinase Inhibitor
8.6.3. VegaF Inhibitor
9. Kidney Cancer or Renal Cancer Market, by Stage
9.1. Introduction
9.2. Localized
9.3. Locally Advanced
9.4. Metastatic
10. Kidney Cancer or Renal Cancer Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line Or Higher
11. Kidney Cancer or Renal Cancer Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Center
11.3. Cancer Institute
11.4. Home Care
11.5. Hospital
12. Kidney Cancer or Renal Cancer Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Kidney Cancer or Renal Cancer Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Kidney Cancer or Renal Cancer Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Kidney Cancer or Renal Cancer Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. Merck & Co., Inc.
16.3.3. Pfizer Inc.
16.3.4. F. Hoffmann-La Roche AG
16.3.5. AstraZeneca plc
16.3.6. Exelixis, Inc.
16.3.7. Novartis AG
16.3.8. Ipsen S.A.
16.3.9. Eisai Co., Ltd.
16.3.10. Merck KGaA
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. KIDNEY CANCER OR RENAL CANCER MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. KIDNEY CANCER OR RENAL CANCER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. KIDNEY CANCER OR RENAL CANCER MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. KIDNEY CANCER OR RENAL CANCER MARKET: RESEARCHAI
FIGURE 26. KIDNEY CANCER OR RENAL CANCER MARKET: RESEARCHSTATISTICS
FIGURE 27. KIDNEY CANCER OR RENAL CANCER MARKET: RESEARCHCONTACTS
FIGURE 28. KIDNEY CANCER OR RENAL CANCER MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. KIDNEY CANCER OR RENAL CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY MTOR INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY MTOR INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY MULTIKINASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY MULTIKINASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY VEGAF INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY VEGAF INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY LOCALIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY LOCALIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY LOCALLY ADVANCED, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY LOCALLY ADVANCED, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY METASTATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY METASTATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THIRD LINE OR HIGHER, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THIRD LINE OR HIGHER, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY CANCER INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY CANCER INSTITUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 106. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 107. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 108. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 109. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 110. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 111. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 112. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 113. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 114. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 115. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. CANADA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 122. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 123. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 124. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 125. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 192. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 193. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 194. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 195. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 196. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 197. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 198. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 199. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 200. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 201. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. GERMANY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 206. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 207. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 208. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 209. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 210. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 211. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 212. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 213. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 214. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 215. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. FRANCE KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 234. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 235. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 236. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 237. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 238. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 239. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 240. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 241. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 242. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 243. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. ITALY KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 248. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 249. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 250. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 251. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 252. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 253. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 254. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 255. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 256. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 257. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. SPAIN KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 284. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. SAUDI ARABIA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 298. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 299. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. SOUTH AFRICA KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. DENMARK KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 304. DENMARK KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 305. DENMARK KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 306. DENMARK KIDNEY CANCER OR RENAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 307. DENMARK

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Kidney Cancer or Renal Cancer Market report include:
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • AstraZeneca plc
  • Exelixis, Inc.
  • Novartis AG
  • Ipsen S.A.
  • Eisai Co., Ltd.
  • Merck KGaA

Related Topics

Related Reports

Kidney Cancer Drugs Market by Cancer Type (Renal Cell Carcinoma, Renal Sarcoma, Transitional Cell Carcinoma), Treatment Type (Chemotherapy, Hormone Therapy, Immunotherapy), Route Of Administration, Dosage Form, End User - Global Forecast 2025-2030 - Product Image

Kidney Cancer Drugs Market by Cancer Type (Renal Cell Carcinoma, Renal Sarcoma, Transitional Cell Carcinoma), Treatment Type (Chemotherapy, Hormone Therapy, Immunotherapy), Route Of Administration, Dosage Form, End User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Kidney Cancer Therapeutics and Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Kidney Cancer Therapeutics and Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 140 Pages
  • Global
From
Kidney Cancer Drugs Market Report and Forecast 2025-2034 - Product Image

Kidney Cancer Drugs Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Kidney Cancer Therapeutics & Diagnostics Market Analysis & Forecast 2024-2034: Market By Cancer Type; By Component (Drugs (Therapeutic Class Pharmacologic Class, Diagnostics; By End-user; and By Region - Product Image

Kidney Cancer Therapeutics & Diagnostics Market Analysis & Forecast 2024-2034: Market By Cancer Type; By Component (Drugs (Therapeutic Class Pharmacologic Class, Diagnostics; By End-user; and By Region

  • Report
  • 145 Pages
  • Global
From
Japan Kidney Cancer Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F - Product Image

Japan Kidney Cancer Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F

  • Report
  • 80 Pages
  • Japan
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.